The Phase III INO-VATE trial (NCT01564784) showed improved rates of complete remission and overall survival in relapsed/refractory acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin compared to standard therapy. In this video, recorded at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, David Marks, MBBS, PhD, FRACP, FRCPath, of University Hospitals Bristol NHS Foundation Trust, Bristol, UK, discusses the key findings from this trial, and outlines new statistical approaches that further emphasize the benefits of this therapy when compared to the standard of care.
INO-VATE: improving ALL outcomes with inotuzumab
